Response to: 'Neuroinflammatory events after anti-TNFα therapy' by Kaltsonoudis et al
- PMID: 32434821
- DOI: 10.1136/annrheumdis-2020-217802
Response to: 'Neuroinflammatory events after anti-TNFα therapy' by Kaltsonoudis et al
Keywords: arthritis, psoriatic; arthritis, rheumatoid; epidemiology; spondylitis, ankylosing; tumor necrosis factor inhibitors.
Conflict of interest statement
Competing interests: TIK has received personal fees from Novartis. MM has received grants from Novartis and Biogen, and has received personal fees from Novartis, Biogen, Merck, Sanofi Genzyme and Teva. FTS has received grants and personal fees from Biogen, Merck, Novartis, Sanofi Genzyme and Roche. JA has received grants from AbbVie, BMS, Eli Lilly, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi and UCB. LD has received grants from BMS and has received personal fees from Eli Lilly and Galderma.
Comment on
-
Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden.Ann Rheum Dis. 2020 May;79(5):566-572. doi: 10.1136/annrheumdis-2019-216693. Epub 2020 Mar 11. Ann Rheum Dis. 2020. PMID: 32161058
-
Neuroinflammatory events after anti-TNFα therapy.Ann Rheum Dis. 2022 May;81(5):e73. doi: 10.1136/annrheumdis-2020-217723. Epub 2020 May 20. Ann Rheum Dis. 2022. PMID: 32434825 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical